Needham Maintains a Buy on Autolus Therapeutics (AUTL), Sets a $10 PT

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best biotech penny stocks to buy right now. On July 21, analyst Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) with a $10.00 price target.

A laboratory technician carefully studying a microscope with a biopharmaceutical product inside.

The analyst told investors that the conditional EU approval of Aucatzyl (obe-cel) for adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is a notable milestone for Autolus Therapeutics plc (NASDAQ:AUTL), adding that Aucatzyl has already attained conditional approval in the UK and a launch is expected soon.

Blum further reasoned that the US market is showing early demand, corroborated by $9 million in sales for fiscal Q1 2025. When considered in conjunction with the estimated sales growth, these factors support the optimistic rating for Autolus Therapeutics plc (NASDAQ:AUTL).

Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer and focuses on chimeric antigen receptor (CAR) T cell therapy.

The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies.

While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.